GeneNews’ Innovative Diagnostic Laboratory J-V Launches Beckman Coulter’s Prostate Health Index (phi) Across U.S.
Toronto, Canada (April 24, 2014): GeneNews Limited (TSX:GEN) (“GeneNews” or the “Company”) today announced that its recently formed joint venture, Innovative Diagnostic Laboratory LLP ("IDL"), has added Beckman Coulter Diagnostics’ Prostate Health Index (phi) to its menu of advanced cancer assays and has initiated a commercial roll out of this groundbreaking test across the United States. Read the full article.
A New Test Three Times
More Specific in Detecting
Our Joint Venture, Innovative Diagnostic Laboratory (IDL) has recenty added Beckman Coulter Diagnostics’ Prostate Health Index (phi) to its menu of advanced cancer assays..
The phi test is a simple, non-invasive blood test that is three times more specific in detecting
prostate cancer(1) than PSA (prostate-specific antigen). While PSA is currently the most widely used screening test for prostate cancer, it is widely recognized that PSA results can often indicate the possibility of prostate cancer when none is present.
IDL has initiated a commercial roll out of this
groundbreaking test across the United States
1. Beckman Coulter U.S. Prostate Cancer Pivotal Study Report .